Cancer Discov. 2018 Dec;8(12):OF4. doi: 10.1158/2159-8290.CD-NB2018-137. Epub 2018 Oct 23.
The FDA approved duvelisib, a PI3Kδ/PI3Kγ inhibitor, for patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma who have received at least two prior therapies. The agency also granted the drug an accelerated approval for patients with relapsed/refractory follicular lymphoma following at least two other therapies.
美国食品药品监督管理局（FDA）批准了PI3Kδ/PI3Kγ抑制剂度维利塞，用于既往至少接受过两种治疗的复发/难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者。该机构还批准该药物用于在至少接受过另外两种治疗后复发/难治性滤泡性淋巴瘤患者的加速批准。
